A comparison of the two groups of patients showed that there was no difference in age, gender, ethnicity, melanoma subtype, M category, BRAF mutational status, cKIT mutational status and the use of non-PD1 inhibitor systemic therapies before or after PD1-inhibitor treatment (Table 4). This evidence concerns the gene BRAF and melanoma.